These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Indications and limitations of fibrinolytic therapy for central artery occlusion (author's transl)].
    Author: Leydhecker W, Krieglstein GK, Brunswig D.
    Journal: Klin Monbl Augenheilkd; 1978 Jan; 172(1):43-6. PubMed ID: 628182.
    Abstract:
    Fibrinolytic therapy was started 90 min after central retinal occlusion in a 62-year-old male patient, but the retinal function did not recover. Another patient, aged 64 years, with occlusion of a retinal artery branch, had therapy started only 6 hours after the event and showed full recovery as was documented by angiography. General contraindications against fibrinolytic therapy are: hypertension over 200 mm Hg, arteriosclerosis, diabetes with retinal changes, previous cerebral insults, malignancy or ulcer, hepatocirrhosis, recent surgical or angiographic interventions, renal insufficiency, pregnancy, cogenital or acquired abnormal blood coagulation. If these contraindications do not apply, fibrinolytic therapy of central retinal arterial obstruction is recommended provided this therapy can be started not later than 6 hours after the event. Occlusions of the central retinal vein should have fibrinolytic therapy only if there are very few haemorrhages and if the occlusion is not older than 24 hours.
    [Abstract] [Full Text] [Related] [New Search]